



Jefferies' 2015 Global Healthcare Conference
Investor Presentation
June 2015

Legal Disclaimer

Forward Looking Statements

Certain statements in this presentation concerning the potential spinoff of the orthobiologics and spinal fusion hardware business, the anticipated timing of the spin-off, the anticipated management of the business to be spun-off, the anticipated net sales and market positions, and the outlook for orthobiologics and spinal fusion hardware business as a separate business constitute forward-looking statements and are based upon management's expectations and beliefs concerning future events. There can be no assurance that the proposed transaction or these future events will occur as anticipated, if at all, or that actual results will be as expected. Forward-looking statements speak only as of the date they were made, and we undertake no obligation to publicly update them. For a description of certain factors, such as the Company's ability to respond to the changes in its end markets that could affect demand for the Company's products; the ability to achieve anticipated growth rates, margins and scale and to execute on our strategy generally; unanticipated changes in business relationships with customers or their purchases from the Company; weakness in global or regional economic conditions and financial markets; the ability to achieve satisfactory operating results in the integration of acquired companies; uncertainties related to the Company's ability to realize the anticipated benefits of the spin-off, including new focus and anticipated growth; the inability to establish or maintain certain business relationships between the Company and Integra; demand for and market acceptance of risks for new and existing products; future actions of regulatory bodies and other governmental authorities, including the FDA and foreign counterparts; product quality or patient safety concerns leading to product recalls, withdrawals, launch delays, litigation, or declining sales; U.S. healthcare reform and other global austerity measures; reimbursement and rebate policies of government agencies and private payers; product development risks; additional indications and therapeutic applications for medical products, biologics, and medical devices; timely submission and approval of regulatory filings; inventory reductions or fluctuations in buying patterns; the availability of acceptable raw materials and component supply; the ability to enforce company patents; and foreign currency fluctuations, that could negatively impact the orthobiologics and spinal fusion hardware business.

Additional factors are discussed in the Company's filings with the Securities and Exchange Commission, including the Company's Form 10 in connection with the spin-off. Except as required by the federal securities laws, the company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Legal Disclaimer

Basis of Presentation

The information included in this presentation about SeaSpine assumes the completion of the transfer by Integra LifeSciences Holdings Corporation of its spinal fusion hardware and orthobiologics business to the Company and the spin-off of SeaSpine. SeaSpine's historical financial data presented herein is derived from the consolidated financial statements and accounting records of Integra LifeSciences Holdings Corporation using the historical results of operations and historical costs basis of the assets and liabilities that comprised its orthobiologics and spinal fusion hardware business spine and orthobiologics business and give effect to allocations of expenses from Integra LifeSciences Holdings Corporation. This historical financial data is not indicative of our future performance and does not reflect what SeaSpine's financial position, results of operations and cash flows would have been had it been a separate stand-alone entity.

Today's Presenters

Proven team with **significant spine and medical technology experience**

Keith Valentine

President* and Chief Executive Officer



- **20+ years** of spine experience
- Former President and COO of NuVasive
- Former VP Marketing at Danek
- Third public spine company – previous management roles in sales, marketing, operations, manufacturing and regulatory

John Bostjancic

Chief Financial Officer



- **16+ years** of finance and operations experience
- Former SVP Global Supply Chain and SVP Finance for Integra
- Public accounting experience in the PwC business assurance group


*President effective upon spin

The SeaSpine Investment Opportunity

Pure-play spine company – **repositioning for agility, innovation & growth**

-  Orthobiologics and spinal fusion hardware portfolio with **robust pipeline of new product launches expected in next 24 months**
-  Orthobiologics platform with **proprietary in-house development and manufacturing know-how** that is nearly half of revenue
-  **Strong balance sheet** post-spin and disciplined approach to fund growth initiatives
-  **Proven management team** with 100+ years of spine and broader medical technology experience

18 Years of Know-How in Spine and Orthobiologics



SeaSpine Spin-off From Integra Q3 2015E



Positioned for innovation and future growth

Balanced Orthobiologics and Spine Company

Infrastructure in place to facilitate **scalable growth**

- Emerging player in \$5.2B US orthobiologics and spine market*
- Integrated company with ~\$140M in orthobiologics and spinal fusion hardware revenue
- Dedicated cadaveric training facility
- Established infrastructure to propel growth
 - Strong quality and compliance systems in place
 - Scalable IT systems with global Oracle ERP platform

* Based on 2014 iData report.

Vista, California Facility
Headquarters, Spinal Fusion Hardware
Operations and Distribution





Irvine, California Facility
Orthobiologics Manufacturing and Distribution



Balanced Portfolio of Products


Orthobiologics

- Used to facilitate bone fusion
- Broad range of traditional and advanced bone graft substitutes
- Portfolio of products containing a range of biological properties needed to encourage bone growth



Product Category Sales

2014 Revenue: \$139M



OUS Sales ~10% of 2014

Spinal Fusion Hardware

- Broad offering:
 - MIS
 - Complex spine and deformity
 - Degenerative
- Used in lumbar, thoracic and cervical spine



Strategic Repositioning to Accelerate Growth

1 Strategic Focus on Spine

- Agility, faster decision, focused execution
- Aligned to better meet customer and market needs

2 Growth-Oriented Transformation

- Expansion of sales distribution and loyalty
- Investment in spinal fusion hardware sets; low capital requirement for orthobiologics
- Increased R&D for accelerated new product launches

3 Financial Flexibility

- Well-capitalized with \$47M in cash
- Debt-free balance sheet
- Sufficient levers to enable growth

4 Accountable Culture

- Management focused on attracting and retaining key talent
- Incentive programs aligned to objectives


Spine Market Dynamics

Stabilizing Market Trends

- Price pressure & Reimbursement pressure mitigating
- Physician Owned Distributorships market share declining
- FDA review time / Innovation cycles improving

Market Success Drivers

- Focus
- Broad & differentiated portfolio
- Targeted commercial investments
- Innovative new products
- Strong balance sheet




Note: Size of bubble represents Spine & Orthobiologics revenue.

Orthobiologics Market

- Growing 3.4% 2014 – 2021
- **#4 position** of US bone graft substitutes market with estimated **8.6% share**

Additional \$700M opportunity in stem cells, cell therapy & growth factors

\$5.2B Total Addressable US Spine Market *



¹ Based on 2014 iData report.

Clinical Need for Orthobiologics in Spinal Fusion

In spinal fusion procedures, tissue between two vertebrae is removed. A successful fusion results when bone grows to fill that void.

Three key elements to bone formation:

1



Osteoconduction: Bone formation by a matrix and scaffold

2



Osteoinduction: Bone formation by the induction of mesenchymal stem cells into bone-forming cells

3



Osteogenesis: New bone is produced through the presence of osteogenic cells found in autograft or bone marrow aspirate

Technology Advantage Example: Accell



Accell bone matrix's increased surface area advantage

- Higher surface area and more porous structure
- Provides early accessibility to bone proteins compared to standard DBM




Particulate DBM



Dispersed ABM

Combining ABM and DBM provides immediate + sustained accessibility to bone proteins



Osteoinductive Potential – *In Vitro* Measurement

Accell Evo3

Accell Evo3 is our most advanced orthobiologic technology




Accell EVO3

- Highest concentration of Accell Bone matrix
- Particulate DBM combined with Dispersed ABM and RPM carrier
- Provides both early and sustained access to naturally occurring bone proteins and growth factors

Highest Concentration of Accell Bone Matrix



Case Study Radiographs



Superior Handling

- Unique biocompatible reverse-phase medium carrier
 - Moldable
 - More viscous to resist irrigation and minimize graft migration
 - Packable into virtually any size or shape defect



Robust, Moldable Putty With Exceptional Handling And Containment Characteristics



Spinal Fusion Hardware Market

- Growing 0.7% 2014 – 2021
- **Interbody devices (IBD)** segment growth estimate of 2.9% 2014 – 2021

\$5.2B Total Addressable US Spine Market*



* Based on 2014 iData report.


Extensive Line of Spinal Fusion Hardware Products

MIS, complex spine, deformity and degenerative solutions

Minimally Invasive Surgery

Market shift from open to MIS procedural approaches


- Expandable interbody device to minimize insertion force needed for either posterior or TLIF procedures
- iPassage MIS Retractor and NewPort Tube System
- NewPort MIS



Complex Spine and Deformity

Revisions, more complicated constructs and clear clinical need

- Daytona Deformity System
- Coral Stainless Steel
- VuMesh




Degenerative


Largest market segment and procedure base

Opportunity to refresh SeaSpine's broad portfolio


- Hollywood NanoMetalene IBD for TLIF procedures
- Malibu and Coral screw and rod systems
- Zuma-C Cervical Anterior Fixation System



Technology Advantage Example: NanoMetalene




Pre clinical histology slide showing typical fibrous layer between PEEK implant and bone



Pre clinical histology slide showing thin NanoMetalene layer with direct bone apposition to implant



- High energy, low temperature atomic fusion deposition surface treatment
- Sub-micron layer of commercially pure titanium covers entire implant surface
- Does not affect mechanical properties or imaging characteristics of PEEK
- Proprietary, licensed technology exclusive to SeaSpine for spine applications



Hollywood NanoMetalene radiograph demonstrating maintenance of positive imaging characteristics




Hollywood NanoMetalene IBD



Financial Overview


Historical Revenue Performance Prior to Separation

Annual



Orthobiologics: 2.6% 2012–2014 CAGR
Total Revenue: -3.0% 2012–2014 CAGR

First Quarter



2014 Geographic Revenue Mix: US: ~90%, Int'l ~10%

Renewed Commitment to Invest in R&D



Expandable IBD



Ventura NanoMetalene IBD



Vu aPOD-L Lateral IBD



Cambria NanoMetalene




Cabo Anterior Cervical Plate



Osteoinductive DBM Strip

SeaSpine Product Launches



Next Generation Programs

- Cervical Stand-Alone System
- Modular Pedicle Screw platform
- Small Stature System

Financial Highlights

Strong financial position post-spin

Balanced revenue base from which to fund future growth

Well-capitalized at spin-off with cash to support investments for growth and no debt

Disciplined approach to invest in R&D and commercial footprint

Scalable support functions and technology to foster growth

The SeaSpine Investment Opportunity

Pure-play spine company – **repositioning for agility, innovation & growth**

-  Orthobiologics and spinal fusion hardware portfolio with **robust pipeline of new product launches expected in next 24 months**
-  Orthobiologics platform with **proprietary in-house development and manufacturing know-how** that is nearly half of revenue
-  **Strong balance sheet** post-spin and disciplined approach to fund growth initiatives
-  **Proven management team** with 100+ years of spine and broader medical technology experience



Thank You